Compugen Ltd.

How big is Compugen Ltd.?

As of Jun 18, Compugen Ltd. has a market capitalization of 154.30 million, with net sales of 27.58 million and a net profit of -14.14 million over the last four quarters.

Market Cap: As of Jun 18, Compugen Ltd. has a market capitalization of 154.30 million, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Compugen Ltd. reported net sales of 27.58 million and a net profit of -14.14 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 54.91 million and total assets of 115.00 million.

What does Compugen Ltd. do?

Compugen Ltd. is a therapeutic discovery company focused on drug target discovery and developing therapeutics, with a market cap of $154.30 million and recent net sales of $2 million. As of March 2025, it reported a net profit loss of $7 million.

Overview:<BR>Compugen Ltd. is a therapeutic discovery company in the Pharmaceuticals & Biotechnology industry, focusing on drug target discovery and the development of therapeutics.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -7 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 154.30 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.81 <BR>Return on Equity: -24.77% <BR>Price to Book: 2.70<BR><BR>Contact Details:<BR>Address: Azrieli Center, 26 Harokmim St. Bldg D, HOLON None: 5885849 <BR>Tel: 972 3 7658585 <BR>Fax: 972 3 7658555 <BR>Website: http://cgen.com/

Should I buy, sell or hold Compugen Ltd.?

Who are in the management team of Compugen Ltd.?

As of March 2022, the management team of Compugen Ltd. includes Mr. Paul Sekhri (Chairman), Dr. Anat Cohen-Dayag (CEO), and several directors: Dr. Jean-Pierre Bizzari, Mr. Gilead Halevy, Dr. Kinneret Livnat Savitsky, Mr. Eran Perry, and Dr. Michal Preminger. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Compugen Ltd. includes the following individuals:<BR><BR>- Mr. Paul Sekhri, Chairman of the Board<BR>- Dr. Anat Cohen-Dayag, President, Chief Executive Officer, and Director<BR>- Dr. Jean-Pierre Bizzari, Director<BR>- Mr. Gilead Halevy, Director<BR>- Dr. Kinneret Livnat Savitsky, Director<BR>- Mr. Eran Perry, Director<BR>- Dr. Michal Preminger, Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is Compugen Ltd. technically bullish or bearish?

As of May 22, 2025, the trend is mildly bearish, with daily moving averages indicating bearishness, weekly indicators showing mild bullishness, and monthly indicators leaning bearish.

As of 22 May 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish outlook, while weekly MACD and KST show a mildly bullish signal. However, the monthly indicators, including Bollinger Bands and KST, lean towards a bearish stance. The RSI shows no clear signal in both weekly and monthly time frames. Overall, while there are some mildly bullish signals in the weekly data, the prevailing trend remains bearish.

Is Compugen Ltd. overvalued or undervalued?

As of March 4, 2025, Compugen Ltd. is considered risky and overvalued due to negative financial metrics, including a Price to Book Value of 2.85, an EV to EBITDA of -4.01, and a Return on Equity of -24.77%, alongside a significantly lower P/E ratio of -10.91 compared to peers, and a stock performance of -17.26% over the past year versus the S&P 500's 10.26% return.

As of 4 March 2025, the valuation grade for Compugen Ltd. has moved from expensive to risky. The company is currently assessed as overvalued given its negative financial metrics and performance indicators. Key ratios include a Price to Book Value of 2.85, an EV to EBITDA of -4.01, and a Return on Equity (ROE) of -24.77%. <BR><BR>In comparison to peers, Compugen Ltd. has a significantly lower P/E ratio of -10.91, while Immunome, Inc. and CARA Therapeutics, Inc. have P/E ratios of -4.55 and -6.24, respectively. This indicates that Compugen is underperforming relative to its peers in the same risky valuation category. Additionally, the company's stock has underperformed against the S&P 500 over the past year, with a return of -17.26% compared to the index's 10.26%, further reinforcing the notion that it is overvalued.